LaQuita Jones, DO
- Member, Division of Oncology
- Associate Professor, UC Department of Pediatrics
- laquita.jones@cchmc.org
- Board Certified
About
Biography
I first developed a sincere interest in pediatric oncology during a medical school rotation, where I witnessed the resilience of children with cancer. Thereafter, my desire to impact therapeutic innovation for the field of pediatric oncology drove me to understand the underlying mechanisms behind resistance to targeted therapies and novel targeted therapy combinations in the treatment of acute myeloid leukemia (AML).
Exposure to various patients during my residency and fellowship increased my interest in pediatric AML specifically. Having those clinical experiences made me acutely aware of the need to continue improving therapies for AML.
I am board certified in pediatrics and pediatric hematology/oncology, and I completed my fellowship in pediatric hematology/oncology in 2018.
So far during my career, I’ve been honored to receive:
- St. Baldrick's Fellowship Award (2017 to 2020) from the St. Baldrick's Foundation, which funds childhood cancer research
- CT2 Scholar (2019 to 2020) funded by the Clinical & Translational Sciences Awards Program (CTSA)
- KL2 Award (2020) funded by the CTSA and National Institutes of Health (NIH)
DO: Ohio University Heritage College of Osteopathic Medicine, Athens, OH, 2012.
Residency: Pediatrics, Nationwide Children's Hospital, Columbus, OH, 2015.
Fellowship: Pediatric Hematology and Oncology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 2018.
Certification: Pediatrics.
Interests
Pediatric leukemia and lymphoma
Services and Specialties
Interests
Targeted therapeutics for FLT3 mutant AML and resistance patterns in AML
Research Areas
Publications
IRAK1/4/pan-FLT3 Kinase Inhibitors with Reduced hERG Block as Treatments for Acute Myeloid Leukemia. ACS Medicinal Chemistry Letters. 2025; 16:887-895.
Discovery of IRAK1/4/pan-FLT3 Kinase Inhibitors as Treatments for Acute Myeloid Leukemia. ACS Medicinal Chemistry Letters. 2024; 15:1843-1851.
Clinical outcomes of hypomethylating agents and venetoclax in newly diagnosed unfit and relapsed/refractory paediatric, adolescent and young adult acute myeloid leukaemia patients. British Journal of Haematology. 2024; 205:1055-1066.
IKAROS and MENIN in synergy in AML. Nature Cancer. 2022; 3:528-529.
Targeted Therapy in Pediatric AML: An Evolving Landscape. Pediatric Drugs. 2021; 23:485-497.
Effect of osteopathic manipulative treatment on pulmonary function testing in children with asthma. Journal of Osteopathic Medicine. 2021; 121:589-596.
81030 Utilizing a synergistic drug combination to target relapsed/refractory FLT3 mutant AML. Journal of Clinical and Translational Science. 2021; 5:100.
Methylation profiling of hypomethylating agent response and treatment failure in pediatric and young adult MDS/AML. Journal of Clinical Oncology. 2020; 38:e22502.
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026
© 1999-2025 Cincinnati Children's Hospital Medical Center. All rights reserved.
Patient Ratings and Comments
All patient satisfaction ratings and comments are submitted by actual patients and verified by a leading independent patient satisfaction company, NRC Health. Patient identities are withheld to ensure confidentiality and privacy. Only those providers whose satisfaction surveys are administered through Cincinnati Children’s Hospital Medical Center are displayed. Click here to learn more about our survey